Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme
Open Access
- 10 August 2020
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 63 (10) , 2112-2122
Abstract
Aims/hypothesis: Approximately 10% of total healthcare budgets worldwide are spent on treating diabetes and its complications, and budgets are increasing globally because of ageing populations and more expensive second-line medications. The aims of the study were to estimate the within-trial and lifetime cost-effectiveness of the weight management programme, which achieved 46% remissions of type 2 diabetes at year 1 and 36% at year 2 in the Diabetes Remission Clinical Trial (DiRECT).Methods: Within-trial analysis assessed costs of the Counterweight-Plus intervention in DiRECT (including training, programme materials, practitioner appointments and low-energy diet), along with glucose-lowering and antihypertensive medications, and all routine healthcare contacts. Lifetime cost per quality-adjusted life-year (QALY) was estimated according to projected durations of remissions, assuming continued relapse rates as seen in year 2 of DiRECT and consequent life expectancy, quality of life and healthcare costs.Results: Mean total 2 year healthcare costs for the intervention and control groups were £3036 and £2420, respectively: an incremental cost of £616 (95% CI –£45, £1269). Intervention costs (£1411; 95% CI £1308, £1511) were partially offset by lower other healthcare costs (£796; 95% CI £150, £1465), including reduced oral glucose-lowering medications by £231 (95% CI £148, £314). Net remission at 2 years was 32.3% (95% CI 23.5%, 40.3%), and cost per remission achieved was £1907 (lower 95% CI: intervention dominates; upper 95% CI: £4212). Over a lifetime horizon, the intervention was modelled to achieve a mean 0.06 (95% CI 0.04, 0.09) QALY gain for the DiRECT population and mean total lifetime cost savings per participant of £1337 (95% CI £674, £2081), with the intervention becoming cost-saving within 6 years.Conclusions/interpretation: Incorporating the lifetime healthcare cost savings due to periods of remission from diabetes and its complications, the DiRECT intervention is predicted to be both more effective (QALY gain) and cost-saving in adults with type 2 diabetes compared with standard care. This conclusion appears robust to various less favourable model scenarios, providing strong evidence that resources could be shifted cost-effectively to support achieving remissions with the DiRECT intervention.Trial registration: ISRCTN03267836Keywords
Funding Information
- University of Glasgow
This publication has 23 references indexed in Scilit:
- Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS)British Journal of Diabetes, 2019
- Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trialThe Lancet Diabetes & Endocrinology, 2019
- Economic Costs of Diabetes in the U.S. in 2017Diabetes Care, 2018
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trialThe Lancet, 2018
- Type 2 diabetes in adolescents and young adultsThe Lancet Diabetes & Endocrinology, 2018
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participantsThe Lancet, 2016
- The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trialBMC Family Practice, 2016
- Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costsDiabetic Medicine, 2012
- Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerolDiabetologia, 2011
- Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric SurgeryNew England Journal of Medicine, 2004